• Policy
• Reimb extensions for Keytruda to be rediscussed later
• by Lee, Tak-Sun Oct 13, 2023 05:29am

• Company
• Companies entering the Middle East caught in the crossfire
• by Kim, Jin-Gu Oct 12, 2023 05:38am

• Company
• Bukwang Pharm’s Ozanex lands in major general hospitals
• by Nho, Byung Chul Oct 12, 2023 05:37am

• Opinion
• [Reporter’s View] KRPIA pulls out ‘structural reform' card
• by Eo, Yun-Ho Oct 12, 2023 05:37am

• Policy
• Overseas drug price comparison plan to be announced
• by Lee, Tak-Sun Oct 12, 2023 05:37am

• Policy
• AD drug Dupixent’s fails 1st negotiations for RSA renewal
• by Lee, Tak-Sun Oct 12, 2023 05:37am

• Policy
• 75% of patients who administered Kymriah is not effective
• by Lee, Jeong-Hwan Oct 11, 2023 05:37am

• Policy
• ‘Little progress for NIP support of 9-valent HPV vaccines'
• by Lee, Jeong-Hwan Oct 11, 2023 05:36am

• Policy
• Eisai’s Jyseleca completes negotiations with NHIS for reimb
• by Lee, Tak-Sun Oct 11, 2023 05:36am

• Policy
• Hyaluronic acid eye drops, start to revise the standard
• by Lee, Tak-Sun Oct 11, 2023 05:36am